Meeting
2018 ASCO Annual Meeting
A FARETES study of the efficacy and safety of testosterone in metastatic renal cell carcinoma patients with fatigue.
Authors
Ilya Tsimafeyeu
Kidney Cancer Research Bureau, Moscow, Russia
Ilya Tsimafeyeu , Ruslan Zukov , Pavel Borisov , Anastasia Bondarenko , Kristina Zakurdaeva , Yulia Tishova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03379012
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4569)
DOI
10.1200/JCO.2018.36.15_suppl.4569
Abstract #
4569
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Exploratory endpoints in a FARETES study of the efficacy of testosterone in metastatic renal cell carcinoma (mRCC) patients.
First Author: Ilya Tsimafeyeu
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2012 ASCO Annual Meeting
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
First Author: Marc Ryan Matrana